Skip to content 
Why FDA’s New QMSR is the
End of Reconstructed Compliance
Location-based execution evidence is fast becoming critical during FDA inspections as per the new QMSR updates February 2026 onwards
Why FDA’s New QMSR Redefines "Audit Readiness"
Compliance has always been about the strength of your records. However, as of February 2, 2026, the benchmark for “objective evidence” is shifting. With the FDA’s New Quality Management System Regulation (QMSR) now in effect, the traditional methods of manual logging and retrospective reporting are facing a new level of scrutiny.
It’s no longer just about having the right documentation; it’s about the unbroken link between your records and the physical floor. For the industry veterans who have built robust systems over decades, this update isn’t a replacement of your expertise – it’s an evolution of the tools required to protect your organization in a real-time regulatory landscape.
Get the Whitepaper
What’s Inside
The Shift in Inspection Logic
Why the FDA is moving away from reviewing static SOPs toward scrutinizing the “Data Signal” between your digital intent and physical execution.
The 5 Critical Failure Modes
A diagnostic look at where traditional compliance often collapses under operational stress. From time-bounded control gaps to the breakdown of process rules while work is in motion – all discussed in detail.
The Bottleneck of “Execution Truth”
Why proving the location and status of assets in real-time is becoming the only way to withstand high-pressure inspection scrutiny.
Building an Evidence-Aware Architecture
How to transition from reactive reconstruction to a “living” audit trail that automatically captures execution proof.
Strategic Use Cases
Real-world applications of turning raw location data into inspection-ready evidence for material segregation, quarantine, and root cause analysis.